Publisher： Adis International
ISSN： 1173-5503
Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.479, 2005-01, pp. : 7-7
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
CR oxybutynin cost effective for OAB in France, Austria and the UK
Inpharma, Vol. 1, Iss. 1443, 2004-01 ,pp. :
Access to resources
Recommend
CR oxybutynin cost effective for OAB in France, Austria and the UK
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 455, 2004-01 ,pp. :
SNM vs botulinum toxin A in OAB: cost effectiveness debated
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 578, 2009-01 ,pp. :
Recognition of bipolar disorder relieves substantial cost burden
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 442, 2003-01 ,pp. :
One-year cost of HF substantial in the US
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 455, 2004-01 ,pp. :